1.2600 -0.01 (-0.79%)
After hours: 6:44PM EDT
Previous Close | 1.3500 |
Open | 1.3300 |
Bid | 1.2700 x 2200 |
Ask | 1.2700 x 1800 |
Day's Range | 1.2400 - 1.3300 |
52 Week Range | 0.4920 - 2.3100 |
Volume | 638,803 |
Avg. Volume | 2,043,067 |
Market Cap | 60.088M |
Beta (5Y Monthly) | 1.73 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1010 |
Earnings Date | Mar 11, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.75 |
QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.
Aerpio Pharmaceuticals (ARPO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.